Tokyo Tape
Sign in
← Kaken Pharmaceutical

Half-year report · Q2

4521.TEDINET S100UP1J
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥51.4bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥72.0bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥36.2bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥19.6bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥5.5bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥19.8bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥10.0bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥19.2bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥5.7bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥14.3bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥8.0bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥14.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥187.1bnat 2024-09-30Cons.Assets
Total assets¥171.6bnat 2024-03-31Cons.Assets
Total assets¥171.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥32.7bnat 2024-09-30Cons.Liabilities
Total liabilities¥27.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥154.4bnat 2024-09-30Cons.Net assets
Net assets / equity¥143.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥140.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥67.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥50.6bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥84.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥65.3bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥70.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.3bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥23.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥245m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥2.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥5.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥377.232024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥212.672023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.182023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio82.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio83.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio82.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2024-04-01 → 2024-09-30¥50.1bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2024-04-01 → 2024-09-30¥50.1bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2024-04-01 → 2024-09-30¥18.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2024-04-01 → 2024-09-30¥676m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥51.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥51.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥19.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2023-04-01 → 2023-09-30¥661m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥5.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 490
ItemContextValueUnit
RoyaltyCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember14787000000JPY
RoyaltyCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember－JPY
RoyaltyCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember14787000000JPY
RoyaltyCurrentYTDDuration_ReconcilingItemsMember－JPY
RoyaltyCurrentYTDDuration14787000000JPY
Other incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember－JPY
Other incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember1222000000JPY
Other incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1222000000JPY
Other incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Other incomeCurrentYTDDuration1222000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember50150000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember1222000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember51372000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration51372000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember50150000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember1222000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember51372000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration51372000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember18903000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember676000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember19579000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating incomeCurrentYTDDuration19579000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-11-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第105期中(自　2024年４月１日　至　2024年９月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)科研製薬株式会社
Company name in english cover pageFilingDateInstantKAKEN PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　堀　内　裕　之
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都文京区本駒込二丁目28番８号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03(5977)5007(ダイヤルイン)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経理部長　　伊　東　誠　司
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都文京区本駒込二丁目28番８号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03(5977)5007(ダイヤルイン)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経理部長　　伊　東　誠　司
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00935
Fund codeFilingDateInstant－
Security codeFilingDateInstant45210
Filer name in japaneseFilingDateInstant
Original text (Japanese)科研製薬株式会社
Filer name in englishFilingDateInstantKAKEN PHARMACEUTICAL CO., LTD.

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass